Ig Vena (Human Normal Immunoglobulin (Iv))

Ig Vena is used to replace IgG antibodies in disorders affecting humoral immunity.

• Primary immunodeficiency diseases: restores IgG levels to reduce the frequency and severity of infections.
• Secondary immunodeficiency (e.g., chemotherapy, HIV): supplies exogenous IgG to support immune function during disease‑ or treatment‑induced antibody loss.
• Immune thrombocytopenic purpura (off‑label): may modulate auto‑immune activity and help increase platelet counts.
• Kawasaki disease (off‑label): used to attenuate inflammation and lower the risk of coronary artery complications.

• Human Normal Immunoglobulin consists of pooled IgG antibodies derived from screened donor plasma. After intravenous infusion, the IgG distributes throughout the vascular and extravascular compartments, where it binds to pathogens, toxins, and immune complexes, neutralizing them. The antibodies also interact with Fc receptors on immune cells, modulating complement activation and cytokine release, thereby providing passive immunity and regulating aberrant immune responses.

Ig Vena may be associated with a range of infusion‑related and immunologic reactions.

Common Side Effects

• Headache: mild to moderate pain often occurring during or shortly after infusion.
• Fever and chills: transient rise in body temperature and shaking sensations.
• Nausea or vomiting: gastrointestinal discomfort following administration.
• Fatigue: temporary feeling of tiredness or weakness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction that can include airway obstruction and hypotension.
• Thromboembolic events: clot formation that may lead to vascular occlusion.
• Renal dysfunction: acute kidney injury manifested by reduced urine output or elevated creatinine.

Before initiating Ig Vena therapy, several safety considerations should be observed.

• Baseline IgG assessment: measure serum immunoglobulin levels to determine replacement need.
• Infusion monitoring: observe patients for signs of reactions during the first administration.
• Cardiovascular status: adjust infusion rate in patients with heart failure or hypertension.
• IgA deficiency with anti‑IgA antibodies: avoid use due to risk of severe anaphylaxis.
• Renal function: use caution and monitor renal parameters in patients with existing kidney disease.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with other agents that affect immune function or hemostasis.

Major Interactions (Avoid)

• Live vaccines: concurrent administration may result in inadequate vaccine response or infection.
• Additional immunoglobulin products: co‑administration can increase risk of hyperviscosity and overload.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin, heparin): monitor for altered coagulation parameters and bleeding risk.
• ACE inhibitors: watch for additive hypotensive effects during infusion.
• Diuretics: assess fluid balance to prevent volume depletion.
• Non‑live vaccines: evaluate immune response as passive antibodies may blunt efficacy.